Modulation of the Inflammatory Response in Cardiovascular Disease

Hypertension

Volumn 43, Issue 5, 2004, Pages 924-931

  Granger, D Neil ^a   Vowinkel, Thorsten ^b   Petnehazy, Thomas ^c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adhesion molecules; Angiotensin II; Integrins; Oxidative stress

Indexed keywords

ANGIOTENSIN; BETA2 INTEGRIN; CD11B ANTIGEN; CD31 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CHRONIC INFLAMMATION; ENDOTHELIUM CELL; GENE ACTIVATION; GENE EXPRESSION; INFLAMMATION; LEUKOCYTE ADHERENCE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANGIOTENSIN II; ANIMALS; ANTIGENS, CD40; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CD40 LIGAND; CELL ADHESION MOLECULES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INTEGRINS; MODELS, ANIMAL; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; THROMBOPHILIA;

EID: 2342460463     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000123070.31763.55     Document Type: Short Survey

References (77)

1. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60.
2. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens. 2001;14:44S-54S.
3. Stokes KY, Cooper D, Tailor A, Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med. 2002;33:1026-1036.
4. Tailor A, Granger DN. Role of adhesion molecules in vascular regulation and damage. Curr Hypertens Rep. 2000;2:78-83.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
6. Mulvihill NT, Foley JB, Crean P, Walsh M. Prediction of cardiovascular risk using soluble cell adhesion molecules. Eur Heart J. 2002;23:1569-1574.
7. Cooper D, Stokes KY, Tailor A, Granger DN. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol. 2002;2:165-180.
8. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
9. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
10. Meydani M. Soluble adhesion molecules: surrogate markers of cardiovascular disease? Nutr Rev. 2003;61:63-68.
11. King PD, Sandberg ET, Selvakumar A, Fang P, Beaudet AL, Dupont B. Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. J Immunol. 1995;154:6080-6093.
12. Komatsu S, Flores S, Gerritsen ME, Anderson DC, Granger DN. Differential up-regulation of circulating soluble and endothelial cell intercellular adhesion molecule-1 in mice. Am J Pathol. 1997;151:205-214.
13. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003;101:2661-2666.
14. Lehr HA. Microcirculatory dysfunction induced by cigarette smoking. Microcirculation. 2000;7:367-384.
15. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med. 2002;30(suppl):S214-S219.
16. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, Messmer K. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood. 1998;92:507-512.
17. Massberg S, Enders G, Matos FC, Tomic LI, Leiderer R, Eisenmenger S, Messmer K, Krombach F. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood. 1999;94:3829-3838.
18. Kirton CM, Nash GB. Activated platelets adherent to an intact endothelial cell monolayer bind flowing neutrophils and enable them to transfer to the endothelial surface. J Lab Clin Med. 2000;136:303-313.
19. Russell J, Cooper D, Tailor A, Stokes KY, Granger DN. Low venular shear rates promote leukocyte-dependent recruitment of adherent platelets. Am J Physiol Gastrointest Liver Physiol. 2003;284:G123-G129.
20. Mannaioni PF, DiBello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflammation Res. 1997;46:4-18.
21. Bazzoni G, Dejana E, Del Maschio A. Platelet-neutrophil interactions, possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica. 1991;76:491-499.
22. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmermann GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1â synthesis. J Cell Biol. 2001;154:485-490.
23. Salter JW, Krieglstein CF, Issekutz AC, Granger DN. Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. Am J Physiol Gastrointest Liver Physiol. 2001;281: G1432-G1439.
24. Strukova SM. Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistry (Mosc). 2001;66:8-18.
25. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104:2395-2400.
26. Ferroni P, Basili S, Vieri M, Martini F, Labbadia G, Bellomo A, Gazzaniga PP, Cordova C, Alessandri C. Soluble P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. Haemostasis. 1999;29:277-285.
27. Tailor A, Granger DN. Hypercholesterolemia promotes P-selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arterioscler Thromb Vasc Biol. 2003;23:675-680.
28. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
29. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-67.
30. Massberg S, Brand K, Gruener S, Page S, Mueller E, Mueller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887-896.
31. Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Miller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514-1518.
32. 12) in platelet activation initiated by binding of von Willebrand factor to platelet GPIba induced by conditions of high shear rate. Circulation. 2002;105:2531-2536.
33. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Hypertension. 2002;40:61-66.
34. Quang-Sang KH, Levenson J, Simon A, Meyer P, Devynck MA. Platelet cytosolic free calcium concentration and plasma cholesterol in untreated hypertensives. J Hypertens. 1987;5:S251-S254.
35. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des. 2003;9:1715-1732.
36. Grisham MB, Granger DN, Lefer DJ. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radic Biol Med. 1998;25:404-433.
37. Granger DN, Benoit JN, Suzuki M, Grisham MB. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol. 1989;257:G683-G688.
38. Akgur FM, Brown MF, Zibari GB, McDonald JC, Epstein CJ, Ross CR, Granger DN. Role of superoxide in hemorrhagic shock-induced P-selectin expression. Am J Physiol Heart Circ Physiol. 2000;279:H791-H797.
39. Stokes KY, Clanton EC, Russell JM, Ross CR, Granger DN. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ Res. 2001;88:499-505.
40. Hickey MJ, Kubes P. Role of nitric oxide in regulation of leucocyte-endothelial cell interactions. Exp Physiol. 1997;82:339-348.
41. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol. 1999;276:H1943-H1950.
42. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001;21:2-14.
43. Jones SP, Girod WG, Marotti KR, Aw TY, Lefer DJ. Acute exposure to a high cholesterol diet attenuates myocardial ischemia-reperfusion injury in cholesteryl ester transfer protein mice. Coron Artery Dis. 2001;12:37-44.
44. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med. 2000;109:315-323.
45. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
46. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss. 2003;96:214-221.
47. 1-type angiotensin receptor in oxidative stress and atherogenesis, part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
48. Panes J, Kurose I, Rodriguez-Vaca D, Anderson DC, Miyasaka M, Tso P, Granger DN. Diabetes exacerbates inflammatory responses to ischemia-reperfusion. Circulation. 1996;93:161-167.
49. Burke A, FitzGerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis. 2003;46:79-90.
50. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Implication of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol. 2003;42:453-461.
51. Clarke R, Armitage J. Antioxidant vitamins and risk of cardiovascular disease: review of large-scale randomised trials. Cardiovasc Drugs Ther. 2002;16:411-415.
52. 1 receptor regulation. Circulation. 2002;105:530-536.
53. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
54. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol. 2002;13:505-512.
55. 1-receptor in atherosclerosis. J Hum Hypertens. 2002;16(suppl 3):S26-S33.
56. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL. Endothelial activation by angiotensin II through NF-κB and p38 pathways: involvement of NF-κB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol. 2003;195:402-410.
57. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Invest Drugs. 2002;3:569-577.
58. Alvarez A, Sanz MJ. Reactive oxygen species mediate angiotensin II-induced leukocyte-endothelial cell interactions in vivo. J Leukoc Biol. 2001;70:199-206.
59. 1 receptor antagonists and platelet activation. Nephrol Dial Transplant. 2001;16(suppl 1):45-49.
60. Matys T, Chabielska E, Pawlak R, Kucharewicz I, Buczko W. Losartan inhibits the adhesion of rat platelets to fibrillar collagen: a potential role of nitric oxide and prostanoids. J Physiol Pharmacol. 2000;51:705-713.
61. 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002;40:521-527.
62. Liu YH, Xu J, Yang XP, Yang F, Shesely E, Carretero OA. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension. 2002;39:375-381.
63. 1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst. 2001;2:103-106.
64. 1-receptor blockade in the prevention and reversal of atherosclerosis. J Hum Hypertens. 2002;16(suppl 3):S34-S41.
65. Petnehazy T, Stokes KY, Granger DN. Losartan attenuates the prothrombogenic and pro-inflammatory effects of acute hypercholesterolemia on the microvasculature. Circulation. 2003;108:164.
66. Henn V, Slupsky JR, Graefe M, Anagnostopoulos I, Foerster R, Mueller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
67. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
68. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by co-expressed CD40. Blood. 2001;98:1047-1054.
69. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106:981-986.
70. Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Froland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol. 2003;41:275-279.
71. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316.
72. Lutgens E, Cleutjens KB, Heenmann S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000;97:7464-7469.
73. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
74. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 2002;105:2849-2854.
75. Yndestad A, Kristian Damas J, Geir Eiken H, Holm T, Haug T, Simonsen S, Froland SS, Gullestad L, Aukrust P. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res. 2002;54:175-182.
76. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-2268.
77. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schönbeck U, Blake MA, Gerhard M, Ridker PM, Libby P, Lee RT. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol. 2003;23:e11-14.